cutoff time point based on PK? [NCA / SHAM]

posted by Biostats – India, 2017-11-26 07:36  – Posting: # 18006
Views: 1,693

Dear Sir,

Thanks for your prompt response

As per Methylphenidate FDA draft guidance cut-off time point should be Average of Tmax + 2*SD (Average and SD should be calculated from IR portion).

Can we apply this method for EMA submission?

Can we apply reference-scaling for all seven pk parameters or only for pk parameters from first phase i.e. Cmax(1) & AUC(1) as expected large intra-subject variability in first phase?


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Helmut]

Complete thread:

Activity
 Admin contact
20,242 posts in 4,259 threads, 1,395 registered users;
online 5 (1 registered, 4 guests [including 2 identified bots]).
Forum time (Europe/Vienna): 09:55 CET

Not to be absolutely certain is, I think,
one of the essential things in rationality.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5